Brentuximab Vedotin

證據等級: L5

預測適應症: 10 個

Brentuximab Vedotin: From CD30-Positive Hodgkin Lymphoma to Follicular Lymphoma

One-Sentence Summary

Brentuximab vedotin is a CD30-targeted antibody-drug conjugate (ADC), originally developed and approved for CD30-positive classical Hodgkin lymphoma, relapsed systemic anaplastic large cell lymphoma (sALCL), and CD30-expressing cutaneous T-cell lymphoma. The TxGNN model predicts it may also be effective for Follicular Lymphoma, with 6 clinical trials and 20 publications currently referenced in the evidence pack — though the trial evidence specific to follicular lymphoma is mixed, with several studies terminated or withdrawn.

Quick Overview

Item	Content
Original Indication	CD30-positive classical Hodgkin lymphoma / relapsed systemic anaplastic large cell lymphoma (per trial-evidence text; no formal Norway license record)
Predicted New Indication	Follicular Lymphoma
TxGNN Prediction Score	99.89%
Evidence Level	L3
Norway Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism-of-action data was not available from DrugBank for this evidence pack (Data Gap, High severity). Based on information embedded in the clinical trial and literature evidence itself, brentuximab vedotin is an antibody-drug conjugate: an anti-CD30 monoclonal antibody chemically linked to monomethyl auristatin E (MMAE), a potent microtubule-disrupting cytotoxic agent. The antibody delivers MMAE selectively to CD30-expressing tumor cells, where it is released intracellularly to induce cell-cycle arrest and apoptosis. This mechanism underlies its established efficacy in CD30-positive classical Hodgkin lymphoma, sALCL, and several CD30+ peripheral T-cell lymphoma (PTCL) subtypes.

The relationship between the original indications and follicular lymphoma (FL) is less direct than for other CD30+ lymphoid malignancies. FL is a classically CD20-positive B-cell neoplasm; CD30 expression in FL is heterogeneous and typically low (often <10–20% of cases), which weakens — but does not eliminate — the mechanistic rationale for CD30-targeted ADC therapy in this population.

This weaker mechanistic fit is reflected in the trial record: of six identified trials touching on FL or closely related B-cell lymphomas, most (NCT04138875, NCT04795869, NCT02623920) were withdrawn before enrollment, and NCT02594163 and NCT01805037 were terminated. Only one trial — NCT04587687, evaluating brentuximab vedotin plus bendamustine specifically in relapsed/refractory FL — remains actively recruiting. This pattern suggests either recruitment difficulty or early signals of limited efficacy, and supports treating the FL prediction as a research hypothesis rather than a near-term repurposing candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT04587687	Phase 2	Recruiting	23	Brentuximab vedotin + bendamustine in relapsed/refractory follicular lymphoma — the only actively recruiting FL-specific trial
NCT02594163	Phase 2	Terminated	25	Rituximab + bendamustine ± brentuximab vedotin in relapsed/refractory CD30-positive DLBCL (not FL-specific)
NCT01805037	Phase 1/2	Terminated	20	Brentuximab vedotin + rituximab as frontline therapy in CD30+/EBV+ lymphomas (mixed population; FL not the primary target)
NCT02623920	Phase 2	Withdrawn	0	Planned brentuximab vedotin + bendamustine + rituximab in CD30+ relapsed/refractory B-cell NHL; withdrawn before enrollment
NCT04138875	Phase 2	Withdrawn	0	Planned risk-stratified rituximab + brentuximab vedotin ± bendamustine in newly diagnosed post-transplant lymphoproliferative disorder; withdrawn before enrollment
NCT04795869	Phase 2	Withdrawn	0	Planned brentuximab vedotin + pembrolizumab in recurrent PTCL; withdrawn before enrollment

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35663281	2022	Review	Leukemia research reports	Overview of immunotherapy in indolent non-Hodgkin lymphoma, including follicular lymphoma as a subtype
32476657	2020	Case Report	The Gulf journal of oncology	Grade I follicular lymphoma transforming to CD30+/ALK1- anaplastic large cell lymphoma, complete response to brentuximab vedotin + high-dose methotrexate
34797505	2022	Cohort	Advances in therapy	Real-world retrospective study of brentuximab vedotin + CEP in untreated CD30+ PTCL (including TFH phenotype)
40517441	2025	Review	Hematological oncology	Overview of PTCL treatment landscape, including CD30-directed therapy
38306597	2024	Review	Blood	Current/upcoming treatment approaches for CD30-negative and CD30-positive PTCL subtypes, incl. brentuximab vedotin + CHP
39644004	2024	Review	Hematology (ASH Education Program)	Incorporating brentuximab vedotin and novel agents into PTCL management
40758949	2025	Phase 2 (LYSA)	Blood advances	Brentuximab vedotin + gemcitabine (GBV) with BV maintenance in relapsed/refractory PTCL
33320379	2021	Cohort	European journal of haematology	Brentuximab vedotin + ICE regimen in relapsed/refractory PTCL
38364196	2024	RCT (Ro-CHOP)	Journal of Clinical Oncology	Final analysis of romidepsin + CHOP vs CHOP in untreated PTCL (context for CD30-directed frontline comparisons)
28340875	2017	Review	Hematology/oncology clinics of North America	Angioimmunoblastic T-cell lymphoma treatment review

Note: Most of the available literature centers on PTCL rather than follicular lymphoma specifically — consistent with the trial evidence showing only one active, dedicated FL trial.

Norway Market Information

Brentuximab vedotin currently holds no marketing authorization in Norway (market_status: 未上市, total_licenses: 0). No license records are available to summarize.

Cytotoxicity

Brentuximab vedotin is an antibody-drug conjugate used exclusively in oncology (CD30-positive lymphoid malignancies) and is therefore evaluated as an antineoplastic agent.

Item	Content
Cytotoxicity Classification	Targeted therapy (Antibody-Drug Conjugate) — anti-CD30 monoclonal antibody linked to the cytotoxic payload monomethyl auristatin E (MMAE)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug-drug interaction data are currently available in this evidence pack — flagged as a Blocking data gap for TFDA/label review.)

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence specific to follicular lymphoma is weak and inconsistent — three of six identified trials were withdrawn before enrollment and two more were terminated, leaving only one actively recruiting Phase 2 trial (NCT04587687). CD30 expression in FL is typically low and heterogeneous, weakening the mechanistic case relative to brentuximab vedotin's established CD30+ indications. Critically, no safety/label data (warnings, contraindications) is currently available, which blocks entry into initial safety screening (S1), and the drug is not marketed in Norway.

To proceed, the following is needed:

TFDA/EMA package insert data — warnings, contraindications, and DDI profile (Blocking gap, DG001)
Confirmed mechanism-of-action documentation from DrugBank (High-priority gap, DG002)
CD30 expression/biomarker stratification data in the target follicular lymphoma population
Mature results from the ongoing NCT04587687 trial (expected completion 2026-12)
A Norway market/registration feasibility assessment before pursuing this repurposing pathway further
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.